Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
Dr. Reinhard Malin
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Campbell Lutyens and J.P. Morgan announce strategic collaboration in the secondary advisory market21.3.2023 14:30:00 EET | Press release
Campbell Lutyens and J.P. Morgan are pleased to announce the establishment of a strategic collaboration to jointly offer their advisory services on single-asset and concentrated multi-asset continuation fund secondary transactions. The offering will enable clients to benefit from Campbell Lutyens’ and J.P. Morgan’s global, market leading secondary and Investment banking advisory practices, respectively. The proposition combines J.P. Morgan’s global top-tier investment banking services with Campbell Lutyens’ leading global placement and secondary advisory platform, creating a best-in-class global offering for single-asset and concentrated multi-asset continuation funds. It will be available for clients across all regions and sectors in which Campbell Lutyens and J.P. Morgan both operate. The offering provides access to Campbell Lutyens’ secondaries expertise focused on fund structuring and capital raising from secondaries and institutional investors along with J.P. Morgan’s M&A services
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After Opening21.3.2023 14:30:00 EET | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced that late in 2022, it successfully released its inaugural First In Human (FIH) manufacturing batch in compliance with current Good Manufacturing Practice (cGMP) standards in its recently expanded Geneva mammalian cell manufacturing facility. The swift execution of this important milestone demonstrates the capabilities in cell line development (CLD) and biologics manufacturing of KBI and Selexis, allowing clients to accelerate clinical research timelines. In July 2022, KBI and Selexis announced the completion of the fully integrated, 8,733 square-meter site combining Selexis’ Cell Line Development services and KBI’s development and manufacturing services. This milestone comes only five months after starting operations at the combined facility. “Delivering this first batch affirms KBI’s commitment to helping pharmaceutical and biotechnology companies across the world achieve their manufacturing goals,” said Mike Land
Visa Defines New Era of How Money Travels Abroad21.3.2023 14:00:00 EET | Press release
Remittances are not only a lifeline for millions of migrant workers and their families, they are also vitally important for the prosperity of many developing economies around the world. As the amount of global remittance inflows continues to reach new records1, 53% of surveyed consumers are turning to digital apps to send and receive funds around the world. Visa today unveiled its “Money Travels: 2023 Digital Remittances Adoption” research report, a survey of over 14,000 consumers across ten countries, revealing that digital remittances are quickly becoming the most popular way to move money internationally, when compared to going to a physical bank or branch (34%); sending cash, checks or money orders by mail (12%); or giving money to another person who is traveling to their home country (11%). In conjunction with the study, Visa launched “Money Travels,” a new podcast series unearthing how payment-related topics unfold differently in various places around the world and highlighting t
Hansen Powers Intraday Trading for Skellefteå Kraft21.3.2023 12:00:00 EET | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water and communications industries, is pleased to announce a new agreement with Skellefteå Kraft, an energy company operating in Sweden. As part of the agreement, Skellefteå Kraft, will use Hansen Trade for automated intraday trading operations. The intraday trading solution within Hansen Trade will enable Skellefteå Kraft to automate intraday trading operations and reach significant cost savings in balance management. Skellefteå Kraft will thus be able to automate intraday trading operations with a modern and easy-to-use trading solution – thereby allowing the company to produce beneficial outcomes and implement zero-touch automation. This in turn will replace costly, manual interventions, and minimise risks in the real-time intraday market. Stefan Forsgren, Business Area Director, Power System at Skellefteå Kraft commented: “In the current volatile climate, which also encompasses the rap
REPLY: Comwrap Reply Named Adobe 2023 Digital Experience Emerging Partner of the Year - Central Europe21.3.2023 11:30:00 EET | Press release
Comwrap Reply, the Reply Group company that specialises in cloud-native digital experience services has been awarded the prestigious Adobe 2023 Digital Experience Emerging Partner of the Year - Central Europe. The award honours companies that have made leading contributions to Adobe’s business and significantly impacted customer success. This award is the result of a strategic roadmap that started with Adobe in 2008 to provide high-value solutions to customers and organisations throughout the world. This announcement comes after Reply acquired multiple Adobe Specializations in recent years and was named a Platinum Solution Partner in 2022. “Comwrap Reply demonstrated strong collaboration with Adobe Customer Solutions by delivering cloud-native client implementations. They have proven their continued dedication toward growing their Adobe Experience Platform practice in Europe, which contributed significantly to earning this award. We look forward to continuing our strategic partnership
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom